Loading clinical trials...
Loading clinical trials...
A Prospective Study to Assess the Efficacy and Safety of the BlueWind RENOVA iStim™ System in the Treatment of Patients Diagnosed With Overactive Bladder (OASIS - OverActive Bladder StImulation System Study)
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder.
Age
18 - 80 years
Sex
FEMALE
Healthy Volunteers
No
University of California Irvine
Orange, California, United States
Kaiser Permanente
San Diego, California, United States
Norwalk Urology
Norwalk, Connecticut, United States
Florida Urology Partners
Tampa, Florida, United States
Comprehensive Urologic Care
Lake Barrington, Illinois, United States
Regional Urology, LLC
Shreveport, Louisiana, United States
Chesapeake Urology - Hanover
Hanover, Maryland, United States
Chesapeake Urology - Owing Mills
Owings Mills, Maryland, United States
Minnesota Urology
Woodbury, Minnesota, United States
Adult Pediatric Urology & Urogynecology
Omaha, Nebraska, United States
Start Date
June 12, 2019
Primary Completion Date
October 28, 2022
Completion Date
January 24, 2025
Last Updated
September 16, 2025
282
ACTUAL participants
RENOVA iStim™ System
DEVICE
Lead Sponsor
BlueWind Medical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions